Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Guardant

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Investors Business Daily

FDA Approves First Blood Test For Colon Cancer Screening

FDA approves Guardant's Shield test for colon cancer screening in adults aged 45 and above, providing a convenient and accessible method for early detection.

Top News

Guardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood Tests

Guardant Health stock jumped Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

A Hidden AI Stock to Add to Your Portfolio

Many AI techniques are already being used in healthcare, where the highest degree of accuracy is required. One such area is oncology testing and the cancer research programs of Guardant Health.

Barchart

Undervalued Small Caps at Morningstar Include a Boat Maker

Small-caps are the most undervalued sector of the market by capitalization, says Morningstar's Dave Sekera.

The Street

Exact Sciences Rockets As Guardant's Blood Test Pales Vs. Cologuard

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

Investors Business Daily

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance

Guardant Health Inc's (NASDAQ:GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million, driven by the increase in clinical and biopharma testing. Development services and other revenues rose 20% to $12.0 million from $14.9 million in…

Benzinga

People

Dave Sekera

32 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.